Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Sihuan Pharmaceutical (460 HK): Buybacks, Now A Spin-Off

Sihuan Pharma (460 HK) Denies China Resources Approach

Quiddity Advisors

Event-Driven

Sihuan Pharmaceutical Hldgs / Event-Driven

<ul>
<li>On the 12th November 2024, <strong><a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener">Sihuan Pharmaceutical (460 HK)</a></strong> proposed spinning-off the shares of Xuanzhu Biopharm on the main board of Hong Kong.</li>
<li>
<a href="https://www.smartkarma.com/entities/xuanzhu-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:44117:1" rel="noopener"><strong>Xuanzhu Biopharmaceutical</strong></a>'s prospectus is now out. Shares are priced at HK$11.60/share, backing out a market cap of ~HK$6bn vs. Sihuan Pharma's HK$17.4bn market cap. Trading commences on the 15th October.</li>
<li>Sihuan Pharma will hold 49.1% post IPO. Its share price is up 189% YTD. Looks frothy. Then again, so does Hong Kong's IPO market.</li>
</ul>


On the 12th November 2024, Sihuan Pharmaceutical (460 HK) proposed spinning-off the shares of Xuanzhu Biopharm on the main board of Hong Kong.

Xuanzhu Biopharmaceutical's prospectus is now out. Shares are priced at HK$11.60/share, backing out a market cap of ~HK$6bn vs. Sihuan Pharma's HK$17.4bn market cap. Trading commences on the 15th October.
Sihuan Pharma will hold 49.1% post IPO. Its share price is up 189% YTD. Looks frothy. Then again, so does Hong Kong's IPO market.


Sihuan Pharma (460 HK): On Xuanzhu Biopharm's Imminent Spin-Off